Vertex Pharmaceuticals, Inc. (VRTX)
547.74
-0.31
(-0.06%)
USD |
NASDAQ |
Aug 24, 16:00
548.20
+0.46
(+0.08%)
After-Hours: 19:58
Vertex Pharmaceuticals Debt to Equity Ratio : 0.0977 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0977 |
| March 31, 2026 | 0.1026 |
| December 31, 2025 | 0.1091 |
| September 30, 2025 | 0.1059 |
| June 30, 2025 | 0.0889 |
| March 31, 2025 | 0.10 |
| December 31, 2024 | 0.1066 |
| September 30, 2024 | 0.1089 |
| June 30, 2024 | 0.0632 |
| March 31, 2024 | 0.0389 |
| December 31, 2023 | 0.046 |
| September 30, 2023 | 0.0451 |
| June 30, 2023 | 0.0496 |
| March 31, 2023 | 0.0547 |
| December 31, 2022 | 0.0647 |
| September 30, 2022 | 0.0633 |
| June 30, 2022 | 0.071 |
| March 31, 2022 | 0.08 |
| December 31, 2021 | 0.0958 |
| September 30, 2021 | 0.092 |
| June 30, 2021 | 0.0972 |
| March 31, 2021 | 0.1001 |
| December 31, 2020 | 0.1085 |
| September 30, 2020 | 0.0672 |
| June 30, 2020 | 0.0694 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.0825 |
| December 31, 2019 | 0.1106 |
| September 30, 2019 | 0.1237 |
| June 30, 2019 | 0.1296 |
| March 31, 2019 | 0.1412 |
| December 31, 2018 | 0.1333 |
| September 30, 2018 | 0.2023 |
| June 30, 2018 | 0.2207 |
| March 31, 2018 | 0.2479 |
| December 31, 2017 | 0.2989 |
| September 30, 2017 | 0.3278 |
| June 30, 2017 | 0.3402 |
| March 31, 2017 | 0.3656 |
| December 31, 2016 | 0.7269 |
| September 30, 2016 | 0.803 |
| June 30, 2016 | 0.8362 |
| March 31, 2016 | 0.8615 |
| December 31, 2015 | 0.8793 |
| September 30, 2015 | 0.8903 |
| June 30, 2015 | 0.9212 |
| March 31, 2015 | 0.854 |
| December 31, 2014 | 0.7674 |
| September 30, 2014 | 0.7165 |
| June 30, 2014 | 0.459 |
| March 31, 2014 | 0.4397 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Gilead Sciences, Inc. | 2.219 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Regeneron Pharmaceuticals, Inc. | 0.0854 |
| Sionna Therapeutics, Inc. | 0.0304 |
| Biogen, Inc. | 0.4433 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 27.42B |
| Total Liabilities (Quarterly) | 7.175B |
| Shareholders Equity (Quarterly) | 20.25B |
| Current Ratio | 3.185 |
| Net Debt Paydown Yield | -0.05% |